In a breakthrough development, scientists have revealed a potential 35% reduction in deaths from cervical cancer. This represents the most important advance in the treatment of the disease in more than two decades.
Researchers at the renowned UCL Cancer Institute and UCLH have found that a short course of induction chemotherapy, followed by standard chemoradiation treatment, can significantly reduce relapse rates and mortality. This remarkable finding offers new hope for women diagnosed with cervical cancer, which mainly affects those over the age of 30, with approximately 3,200 new cases each year in the UK alone. It is worth noting that cervical cancer is the fourth most prevalent cancer among women worldwide, according to the World Health Organization.
The trial, conducted over a period of 10 years and with the participation of 500 patients from several countries, gave promising results. After five years, an impressive 80% of those who received the combination therapy were alive and 73% showed no signs of cancer recurrence or spread. In comparison, the treatment-as-usual group saw a 72% survival rate, with 64% experiencing no relapse or spread.
Dr Mary McCormack, the trial’s principal investigator, expressed her excitement, stating that this breakthrough represents “the biggest improvement in the outcome of this disease in more than 20 years”.
The accessibility and affordability of the drugs required for induction chemotherapy further enhance the potential for rapid adoption of this improved treatment method. These drugs are already approved for use in patients, making incorporation into standard treatment a relatively quick process. This development marks a potential paradigm shift in the treatment of cervical cancer since 1999, offering hope for better outcomes and reduced mortality rates. The five-year survival rate for cervical cancer is currently around 70%, according to Cancer Research UK, which funded the study.
Professor Jonathan Ledermann, lead author of the results from the UCL Cancer Institute, emphasized the importance of this breakthrough, hailing it as “a major advance in treatment”. Dr McCormack expressed her gratitude to all the patients who took part in the trial, recognizing their invaluable contribution in gathering the evidence needed to improve the treatment of cervical cancer worldwide.
These preliminary results were presented at the European Society of Medical Oncology congress, and the medical community is eagerly awaiting their publication in a peer-reviewed journal. This groundbreaking discovery brings us closer to a future where cervical cancer can be fought more effectively, providing renewed hope and improved treatment options for patients around the world.
the mail Innovative treatment reduces deaths from cervical cancer by 35% appeared first NewsGPT.ai.
Español de Venezuela 
English 